Matthias Kant
Overview
Explore the profile of Matthias Kant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hestvik A, Frederiksen J, Nielsen H, Torkildsen O, Eek C, Huang-Link Y, et al.
Mult Scler Relat Disord
. 2022 Jun;
63:103892.
PMID: 35696880
Background: Teriflunomide 14 mg (Aubagio®) is a once-daily, oral drug approved for the treatment of relapsing forms of multiple sclerosis (MS). While the efficacy and safety of teriflunomide have been...
12.
Riemenschneider M, Hvid L, Ringgaard S, Nygaard M, Eskildsen S, Gaemelke T, et al.
Mult Scler
. 2022 Mar;
28(10):1620-1629.
PMID: 35296183
Background: Potential supplemental disease-modifying and neuroprotective treatment strategies are warranted in multiple sclerosis (MS). Exercise is a promising non-pharmacological approach, and an uninvestigated 'window of opportunity' exists early in the...
13.
Kopp T, Bramow S, Illes Z, Kant M, Kristensen C, Rasmussen P, et al.
Mult Scler Relat Disord
. 2021 Oct;
56:103319.
PMID: 34666241
Background: The number of patients with relapsing remitting multiple sclerosis (RRMS) who convert to secondary progressive (SP) MS is uncertain, and with emerging treatment options for SPMS, it is important...
14.
Pontieri L, Blinkenberg M, Bramow S, Papp V, Rasmussen P, Kant M, et al.
Eur J Neurol
. 2021 Oct;
29(2):496-504.
PMID: 34644452
Background And Purpose: Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited. The aim was to evaluate the effectiveness and safety...
15.
Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen P, Kant M, et al.
JAMA Neurol
. 2021 Aug;
78(10):1197-1204.
PMID: 34398221
Importance: Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary markedly between Denmark and Sweden. The difference in the association of these national strategies with clinical outcomes is unknown. Objective: To...
16.
Papp V, Buron M, Siersma V, Rasmussen P, Illes Z, Kant M, et al.
PLoS One
. 2021 May;
16(5):e0250820.
PMID: 34003862
Objective: Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of...
17.
Theodorsdottir A, Debrabant B, Magyari M, Kant M, Rasmussen P, Malmberg C, et al.
Mult Scler
. 2021 Mar;
27(14):2254-2266.
PMID: 33779361
Objective: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark. Methods: Data were retrieved from The Danish Multiple Sclerosis Registry...
18.
Buron M, Chalmer T, Sellebjerg F, Barzinji I, Danny B, Romme Christensen J, et al.
Neurology
. 2020 Jul;
95(8):e1041-e1051.
PMID: 32636328
Objective: To determine the effectiveness of high-efficacy disease-modifying therapies (heDMTs) vs medium-efficacy disease-modifying therapies (meDMT) as the first treatment choice in treatment-naive patients with multiple sclerosis (MS) on disability worsening...
19.
Buron M, Chalmer T, Sellebjerg F, Frederiksen J, Gora M, Illes Z, et al.
Neurology
. 2019 Mar;
92(16):e1811-e1820.
PMID: 30877188
Objective: To compare on-treatment efficacy and discontinuation outcomes in teriflunomide (TFL) and dimethyl fumarate (DMF) in the treatment of relapsing-remitting multiple sclerosis (RRMS) in a real-world setting. Methods: We identified...
20.
Papp V, Illes Z, Magyari M, Koch-Henriksen N, Kant M, Pfleger C, et al.
Neurology
. 2018 Nov;
91(24):e2265-e2275.
PMID: 30413632
Objectives: To estimate the nationwide population-based incidence, prevalence, and geographical distribution of neuromyelitis optica (NMO) spectrum disorder (NMOSD) in Denmark based on the 2015 International Panel for NMO Diagnosis (IPND)...